Enfamil Gentlease Formula Market Report: Sales Volume, Market Share, Leading Brands & Market Trends

Similac is the best-performing enfamil gentlease formula brand in July 2026, moving 50,000 units across 6 ASINs for 64.9% of Top 10 volume. Bubs follows with 10,000 units (13.0%), ahead of Dr. Brown's on 6,000 units (7.8%).

With 5 brands splitting the Top 10 and 85.7% of volume sitting with three of them, this is a concentrated shelf — the leaders hold multiple listings or one very high-velocity ASIN, so a new entrant competes against established review moats rather than an open field. Average selling prices among the leaders run from $9.99 to $54.54, which frames the price band a competing listing has to justify.

Based on July 2026 data, this shortlist surfaces the two kinds of ASIN worth keeping an eye on — the ones that just broke into the Top 10, and the ones growing fastest month over month. Specifically, one ASIN forced its way in: B09DTG9YRC booked 4K units at $9.99, with ▲ 33.3% MoM change. On the growth side, B09DTGC3MC leads positive momentum with ▲ 100.0% MoM growth on 20K units, with B00L99TS2M close behind at ▲ 100.0% MoM on 2K units.

The two signals carry different weight. A fresh entrant means share has already changed hands — an incumbent gave up its place to make room, so any competitive set drawn up a month ago is now out of date. A steep growth rate works as the earlier warning: it marks demand that is still compounding, usually a month or two before the ranking catches up to it.